Related Experiment Video
Updated: May 28, 2026
07:57
Malachite Green Assay for the Discovery of Heat-Shock Protein 90 Inhibitors
Published on: January 20, 2023
HSP90 inhibitors as therapy for multiple myeloma
Saad Z Usmani1, Gabriela Chiosis
1Myeloma Institute for Research & Therapy, University of Arkansas for Medical Sciences, Little Rock, AZ 72205, USA. susmani@uams.edu
Clinical Lymphoma, Myeloma & Leukemia
|November 1, 2011
Summary
Heat shock protein 90 (HSP90) inhibitors show promise for treating multiple myeloma by targeting key cancer-promoting pathways. This review covers preclinical and clinical data on HSP90 inhibition in multiple myeloma drug development.
Area of Science:
- Molecular biology
- Oncology
- Pharmacology
Background:
- Heat shock protein 90 (HSP90) proteins are crucial molecular chaperones involved in protein folding and maturation.
- HSP90 is abundant in eukaryotic cells, comprising 1-2% of total cellular proteins.
- Elevated HSP90 expression is observed in various malignancies, including multiple myeloma.
Purpose of the Study:
- To provide an overview of HSP90 inhibitors in multiple myeloma.
- To review preclinical data on HSP90 inhibition in multiple myeloma.
- To summarize clinical trial data for HSP90 inhibitors in multiple myeloma treatment.
Main Methods:
- Review of preclinical studies investigating HSP90 inhibitors.
- Analysis of clinical trial data for HSP90 inhibitors in multiple myeloma.
- Synthesis of existing research on HSP90's role in multiple myeloma.
Main Results:
- HSP90 inhibition affects multiple oncogenic pathways critical to myeloma progression.
- HSP90 inhibitors represent a promising therapeutic strategy for multiple myeloma.
- Preclinical and clinical data support the investigation of HSP90 inhibitors.
Conclusions:
- HSP90 is a validated therapeutic target in multiple myeloma.
- HSP90 inhibitors have demonstrated potential in preclinical and clinical settings.
- Further research and clinical trials are warranted to optimize HSP90-targeted therapies for multiple myeloma.
Related Concept Videos
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...